AstraZeneca PLC (LSE:AZN, STO:AZN, NYSE:AZN) announced Monday the admission of 14,120 new ordinary shares of $0.25 each to trading on the Main Market of the London Stock Exchange. The new shares are fully fungible with the company’s existing ordinary shares, according to a statement released through a regulatory filing.
Following this admission, AstraZeneca’s total number of issued ordinary shares stands at 1,551,009,750. The newly admitted shares were issued under the company’s employee share schemes during the period from May 1 to May 31, 2026. The admission was conducted under an existing block admission arrangement dated January 29, 2021.
No prospectus or supplementary prospectus was issued in connection with this share admission. The company confirmed that the new shares are of the same class and carry the same rights as the existing ordinary shares.
The information is based on a press release statement accompanying the company’s filing with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.